UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

MASLD and MetALD: The new nomenclature and the combination with moderate alcohol intake

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

MASLD and MetALD: The new nomenclature and the combination with moderate alcohol intake

Elisabetta Bugianesi 1

Affiliations

1 AOU Città della Salute e della Scienza University of Torino, Torino, Italy, Torino, Italy

Summary

AI Generated

The speaker presented the new steatotic liver disease nomenclature, developed through a consensus of 56 countries and over 200 experts, which replaces NAFLD with an affirmative metabolic-based diagnostic framework and introduces MetALD to capture combined metabolic and alcohol-related injury.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is diagnosed by hepatic steatosis plus at least one of five cardiometabolic criteria: high BMI, high serum glucose, high blood pressure, high plasma triglycerides, or low HDL cholesterol.
MetALD defines patients with both metabolic disease and alcohol consumption between MASLD and ALD thresholds (20-30g to 50-60g per day average intake).
The speaker reported that in a general population study, 7.6% had significant fibrosis, with risk increasing stepwise from MASLD to MetALD to ALD; nearly one-third with 4-5 cardiometabolic risk factors and MetALD-level drinking had significant fibrosis.
Even moderate alcohol consumption can increase fibrosis risk in a dose-dependent interaction with cardiometabolic risk factors, according to the speaker.
General population screening for steatotic liver disease is not advised per the new European guidelines, but patients presenting with fatty liver should be evaluated for underlying causes.
The speaker stated that GLP-1 receptor agonists can lead to steatohepatitis resolution in up to 60% of treated patients, with phase 3 semaglutide results expected in November.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

UEG Postgraduate Teaching Programme Vienna 2024

Topics

Education & Training Hepatobiliary Primary Care

Session

Metabolic dysfunction: Associated steatotic liver disease

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

More Like This:

Diverticulitis

Johannes Kurt Schultz

Episode 4: UEG Journal August Spotlight

Nigel Trudgill

Basic pathophysiology of gastroparesis

Florencia Carbone

Connective tissue disorders

Asma Fikree

Butt problems

Emma V. Carrington

THE MIST1–UFM1–STK38 AXIS REGULATES YAP1 ACTIVITY TO ENABLE PROGENITOR-LIKE REPROGRAMMING OF GASTRIC CHIEF CELLS DURING PALIGENOSIS

Jason Mills

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.